TribsMab CLC, a novel bispecific antibody format solves a manufacturing challenge
Therapeutic mechanism that differs from conventional treatment methods with the target identified from genetic analysis of model animals and IC patients
Designed RANKL fragment peptides (Partial agonist of RANKL) treat fibrosis.
Blockade of novel target, Netrin-4 Unc5B signaling.
Treatment of allergies and mastocytoma with Mast cell targeting antibodies
A new therapeutic mechanism to inhibit cytokine production from topical IL-17-producing cells by CD96 neutralizing antibodies
Treatment of immunological diseases by a new mechanism to control the immune Th1/Th2 balance
Original method and hepatocyte reproduced hepatobiliary function
DR6 mAb promotes Sdc1-DR6 dependent immunosuppressive pathway in autoreactive T cells
A novel technology loosens tight junction of BBB and supports drug transportation into brain.
Selective inhibition of Periostin variant (PN1) by monoclonal antibody
Variant Specific Periostin Neutralization for Diabetic Retinopathy
About Bionauts.jp
